Collplant

Ness Ziona, Israel Founded: 2004 • Age: 22 yrs Listed
Plant-derived collagen is developed for tissue repair and 3D bioprinting.

About Collplant

Collplant is a publicly listed company based in Ness Ziona (Israel) founded in 2004. Plant-derived collagen is developed for tissue repair and 3D bioprinting. It operates in the Healthcare and Technology sectors. Collplant has raised $16.3 million across 12 funding rounds from investors including Ami Sagi, Invesco and Alpha Capital Partners. The company has 57 employees. Collplant has completed 1 acquisition, including LightSolver. Collplant offers products and services including rhCollagen, Collink.3D Bioinks, and Dermal Fillers. Its focus areas include High Tech, 3D Printing, Hardware and 3D Printing Materials. Its legal entity is CollPlant Biotechnologies Ltd.

Company details

The company was founded in 2004 in Ness Ziona, Israel, within the biotechnology sector. Plant-derived collagen and recombinant proteins are produced via a transgenic plant system for medical applications. Recombinant type I human collagen is generated for use in tissue repair, ortho-biologics, wound care, and 3D bioprinting. A dedicated 3D bioprinting division was established in 2017 to support organ and tissue fabrication.

  • Headquarters Ness Ziona, Israel
  • Employees 57
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website collplant.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Collplant Biotechnologies Ltd.
Key Metrics
  • Annual Revenue
    $2.37 M (USD)
    360.39
    as on Dec 31, 2025
  • Net Profit
    -$11.49 M (USD)
    30.83
    as on Dec 31, 2025
  • EBITDA
    -$10.57 M (USD)
    34.8
    as on Dec 31, 2025
  • Total Equity Funding
    $16.3M (USD)

    in 12 rounds

  • Latest Funding Round
    $9.25M (USD), Post-IPO

    Oct 2026

  • Investors
    Invesco

    & 4 more

  • Employee Count
    57
  • Investments & Acquisitions

Products & Services of Collplant

Collplant offers a comprehensive portfolio of products and services, including rhCollagen, Collink.3D Bioinks, and Dermal Fillers.

rhCollagen
Biomaterial

Recombinant human collagen for tissue regeneration applications

Collink.3D Bioinks
3D Bioprinting

Bioinks for manufacturing tissues and organs

Dermal Fillers
Medical Aesthetics

Regenerative products for aesthetic enhancements

Funding Insights of Collplant

Collplant has successfully raised a total of $16.3M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.25 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $16.3M
  • Total Rounds 12
  • Last Round Post-IPO β€” $9.25M
  • First Round $4.5M

    (Jun 2006)

  • Investors Count 5

Latest 10 of 12 funding rounds of Collplant with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2026$9.25MPost-IPO––
–
Feb 2026$4MPost-IPO––
–
Feb 2020$4.45MPost-IPO––
–
Sep 2019$5.5MPost-IPO––
Nov 2017$2MPost-IPO––
Oct 2017$5MPost-IPO––
Feb 2016$2.07MPost-IPO––
–
Dec 2013$1.05MPost-IPO––
–
Apr 2008$8.3MSeries B––
Feb 2007$2MSeries A––
Valuation history

5 investors in total: 4 institutional and 1 angel.

Investors in Collplant

Collplant has secured backing from 5 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Ami Sagi, Invesco and Alpha Capital Partners.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
A family office focused on private equity and investments.
1984alphacapital.com
Pontifax Venture Capital is focused on life sciences investments.
pontifax.comHerzeliya, Israel
Investments are directed toward Israeli technology startups by Docor.
docor.comTel Aviv, Israel
Diversified asset management services are offered globally by Invesco.
invesco.comAtlanta, United States

Ami Sagi

unknown_a7a4a1908ab94b1fa
Premium access

Investor details for Collplant

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Collplant

31 people are tracked at Collplant (12 in leadership, 12 in board & advisors, 7 in team); the tracked headcount is 57.

NameRoleGroup
Yehiel Tal
Chief Executive OfficerLeadership
Oded Shoseyov
CTO DirectorLeadership
Hadas Dreiher Horowitz
VP HRLeadership
Elana Gazal
VP Research And DevelopmentLeadership
Eran Rotem
Deputy CEO & Chief Financial OfficerLeadership
Miriam Rubinchik - Stern
Head Of Research - Regenerative Breast Implant ProgramLeadership
Gal Salinas
Head Of 3dbio-printing & System EngineeringLeadership
Philippe B.
VP Of Regulatory Affairs And Quality AssuranceLeadership
Astrid Dafan-van Dien
Personal Assistant To CEO And Deputy Ceo, CollplantLeadership
Oren Fahimipoor
VP, OperationsLeadership
Guy Ochbaum
Head Of Process DevelopmentLeadership
Jasmine Seror
Director Of R&dLeadership
Elan Penn
Board MemberBoard & advisors
Avri Havron
Board MemberBoard & advisors
Avram Hershko
AdvisorBoard & advisors
Vicki Rosen
AdvisorBoard & advisors
Joseph M. Lane
AdvisorBoard & advisors
Abhay Pandit
AdvisorBoard & advisors
Joseph Zarzewsky
Board MemberBoard & advisors
Roger J. Pomerantz
ChairmanBoard & advisors

11 more people are available in the full profile.

Premium access

Complete people profiles for Collplant

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Collplant

Collplant is a publicly listed company on the NASDAQ with ticker symbol CLGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date30 Jan 2018
  • Listed onNASDAQ: CLGN
  • Listed entityCollPlant Biotechnologies Ltd.
  • Exchange sectorHealth technology
  • ISINIL0004960188
  • Share price$3.91 (-2.74% on the day) · 2026-10-13
  • Market capitalisation$7.4M
  • EPS (diluted, trailing year)$-9.38
  • Volume (last session)48,004

Financials of Collplant

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$2.4M-$11.5M-$10.6M
2024$515,000-$16.6M-$16.2M
2023$11.0M-$7.0M-$6.4M
2022$299,000-$16.9M-$16.0M
2021$15.6M$237,000$838,000
Premium access

Detailed financial statements for Collplant

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Collplant

Collplant has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include LightSolver.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Optical and quantum-inspired devices are developed for optimization solutions.
lightsolver.comTel Aviv, Israel2020Aug 2026β€’β€’β€’β€’
Premium access

Complete acquisition details for Collplant

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Collplant

5 dated milestones of Collplant across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Collplant is founded.
  2. Funding First funding round of $4.5M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires LightSolver.
  5. Funding Latest funding round, Post-IPO, of $9.2M.

Web traffic of Collplant

The website of Collplant (collplant.com) receives about 3.2K visits a month and ranks #8,398,793 among all websites worldwide, #7,356 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.2K

    ▲ 64.3% vs previous month

  • Global rank
    #8,398,793

    among all websites

  • Category rank
    #7,356

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Collplant. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
collegiumpharma.com
100%
13.5K#1,457,207View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Collplant

Premium access

Complete news archive for Collplant

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Collplant

Collplant was founded in 2004 and raised its 1st funding round 2 years after it was founded.

Collplant is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.

Collplant is a funded company, having raised a total of $16.3M across 12 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jun 2006.

Collplant has 57 employees.

Annual revenue of Collplant is $2.37M as on Dec 31, 2025.

The company was founded in 2004 in Ness Ziona, Israel, within the biotechnology sector. Plant-derived collagen and recombinant proteins are produced via a transgenic plant system for medical applications. Recombinant type I human collagen is generated for use in tissue repair, ortho-biologics, wound care, and 3D bioprinting. A dedicated 3D bioprinting division was established in 2017 to support organ and tissue fabrication.

Collplant offers rhCollagen, Collink.3D Bioinks, and Dermal Fillers.

Yes, Collplant is publicly traded on NASDAQ under the ticker symbol CLGN.

Collplant has made 1 acquisition, including LightSolver.

Collplant has 5 investors. Key investors include Ami Sagi, Invesco, Alpha Capital Partners, Pontifax Venture Capital, and Docor.

Collplant operates through Collplant Biotechnologies Ltd..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available